Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 12/20 | 0.45 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | PDE9A | O76083 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29929479 | 1.00 | SMO (0.45) | SMOPROKR1CNR2PIM1PIM3 | |
| SCHEMBL28421081 | 0.85 | CNR2 (0.42) | SMOCNR2 | |
| SCHEMBL22129420 | 0.78 | SMO (0.39) | SMO | |
| SCHEMBL29404134 | 0.77 | SMO (0.42) | SMOCNR2 | |
| SCHEMBL22129464 | 0.77 | SMO (0.41) | SMO | |
| SCHEMBL22153061 | 0.76 | PDE9A (0.41) | SMOPDE9A | |
| SCHEMBL28422543 | 0.75 | PROKR1 (0.38) | SMOPROKR1TYK2LRRK2PDE9A | |
| SCHEMBL12524364 | 0.72 | CHRM4 (0.39) | CNR2KCNH2MCHR1TYK2 | |
| SCHEMBL30937175 | 0.70 | PDE10A (0.50) | PROKR1CNR2 | |
| SCHEMBL11981511 | 0.70 | EGLN2 (0.40) | PROKR1KCNH2TYK2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111333626-B | Phenyl pyrrolidine compounds and uses thereof | 武汉人福创新药物研发中心有限公司 | 2022-10-18 | — | — | CN | disclosed |
| US-20220056014-A1 | PHENYLPYRROLIDINE COMPOUND AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2022-02-24 | — | — | US | disclosed |
| EP-3901146-A1 | PHENYLPYRROLIDINE COMPOUND AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2021-10-27 | — | — | EP | disclosed |
| EP-3901146-A1 | PHENYLPYRROLIDINE COMPOUND AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2021-10-27 | — | — | EP | disclosed |
| CN-111333626-A | Phenyl pyrrolidine compounds and uses thereof | 湖北生物医药产业技术研究院有限公司 | 2020-06-26 | — | — | CN | disclosed |
| WO-2020125627-A1 | PHENYLPYRROLIDINE COMPOUND AND USE THEREOF | 湖北生物医药产业技术研究院有限公司 | 2020-06-25 | — | — | WO | disclosed |
| WO-2020125627-A1 | PHENYLPYRROLIDINE COMPOUND AND USE THEREOF | 湖北生物医药产业技术研究院有限公司 | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056014-A1 | PHENYLPYRROLIDINE COMPOUND AND USE THEREOF | PAH, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, AVPR2 | SMO 4546/4885PROKR1 453/4885CNR2 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.